Asset Details
Do you wish to reserve the book?
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Do you wish to request the book?
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
2019
Overview
Abstract
Context
Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors are still partially unknown. We investigated whether dapagliflozin modulates systemic and renal vascular function and structure, and induces epigenetic modifications.
Subjects and Methods
Forty hypertensive patients with type 2 diabetes were randomly assigned to 4-week treatment with dapagliflozin 10 mg or hydrochlorothiazide (HCT) 12.5 mg. Routine analyses; plasma renin activity; aldosterone, catecholamine, and 24-hour urinary electrolyte levels; flow-mediated dilation (FMD) of the brachial artery; carotid-femoral pulse-wave velocity (PWV); augmentation index; and resistive index and dynamic renal resistive index (DRIN) were measured at baseline and after treatment. Circulating miRNAs (miRs) related to heart failure (miR30e-5p, miR199a-3p), endothelial dysfunction (miR27b and miR200b), and renal function (miR130b-3p, miR21-5p) were assessed and related to the effects of treatments.
Results
Dapagliflozin and HCT marginally lowered blood pressure. Fasting glucose was lowered, whereas 24-hour diuresis, glycosuria, and osmolar clearance were increased by dapagliflozin (P < 0.001 for all), without affecting sodium excretion and glomerular filtration rate. Magnesium levels significantly increased after dapagliflozin treatment (P = 0.02). Neither dapagliflozin nor HCT modified FMD or PWV. DRIN did not vary in the dapagliflozin group, whereas it increased in the HCT group (P = 0.047 for time by treatment interaction). Both treatments induced variations in the expression of some miRs; dapagliflozin, but not HCT, significantly up-regulated miR30e-5p and downregulated miR199a-3p.
Conclusion
A putative epigenetic regulation of the protecting cardiovascular effect exerted by SGLT2 inhibitors was found. Dapagliflozin might exert nephroprotection by preserving renal vasodilating capacity.
Hemodynamic and systemic vascular effects of dapagliflozin undergo epigenetic regulation that favorably affects two miRs involved in heart failure.
Publisher
Endocrine Society,Copyright Oxford University Press,Oxford University Press
Subject
/ Aged
/ Analysis
/ Benzhydryl Compounds - administration & dosage
/ Blood Glucose - drug effects
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - diagnosis
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diuresis
/ Epigenesis, Genetic - drug effects
/ Female
/ Glomerular Filtration Rate - drug effects
/ Glucosides - administration & dosage
/ Humans
/ Hydrochlorothiazide - administration & dosage
/ Hypertension - complications
/ Italy
/ Male
/ Renal Circulation - drug effects
/ Renin
/ Sodium-Glucose Transporter 2 Inhibitors - administration & dosage
